litlas
ログインアカウント作成

Paul A. Bunn

1976–2024 年に発表

別表記
PAUL A. BUNN
166
論文数
44,992
被引用数
115
h 指数
163
i10 指数

被引用数

Paul A. Bunn の年別被引用数1944 年: 被引用 1 件1971 年: 被引用 3 件1976 年: 被引用 2 件1978 年: 被引用 2 件1979 年: 被引用 7 件1980 年: 被引用 6 件1981 年: 被引用 34 件1982 年: 被引用 76 件1983 年: 被引用 126 件1984 年: 被引用 139 件1985 年: 被引用 135 件1986 年: 被引用 109 件1987 年: 被引用 139 件1988 年: 被引用 100 件1989 年: 被引用 97 件1990 年: 被引用 112 件1991 年: 被引用 98 件1992 年: 被引用 73 件1993 年: 被引用 57 件1994 年: 被引用 47 件1995 年: 被引用 58 件1996 年: 被引用 80 件1997 年: 被引用 75 件1998 年: 被引用 65 件1999 年: 被引用 91 件2000 年: 被引用 75 件2001 年: 被引用 100 件2002 年: 被引用 125 件2003 年: 被引用 184 件2004 年: 被引用 190 件2005 年: 被引用 239 件2006 年: 被引用 332 件2007 年: 被引用 376 件2008 年: 被引用 356 件2009 年: 被引用 330 件2010 年: 被引用 372 件2011 年: 被引用 272 件2012 年: 被引用 232 件2013 年: 被引用 285 件2014 年: 被引用 227 件2015 年: 被引用 275 件2016 年: 被引用 288 件2017 年: 被引用 310 件2018 年: 被引用 266 件2019 年: 被引用 868 件2020 年: 被引用 965 件2021 年: 被引用 930 件2022 年: 被引用 680 件2023 年: 被引用 476 件2024 年: 被引用 750 件2025 年: 被引用 367 件2026 年: 被引用 4 件1945〜1970 年は被引用が無いため表示していません1972〜1975 年は被引用が無いため表示していません1977 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,314 件、この内訳の 30.6%中国: 引用元論文 1,642 件、この内訳の 11.6%日本: 引用元論文 897 件、この内訳の 6.4%イギリス: 引用元論文 660 件、この内訳の 4.7%イタリア: 引用元論文 637 件、この内訳の 4.5%ドイツ: 引用元論文 607 件、この内訳の 4.3%フランス: 引用元論文 558 件、この内訳の 4%カナダ: 引用元論文 433 件、この内訳の 3.1%スペイン: 引用元論文 424 件、この内訳の 3%オランダ: 引用元論文 352 件、この内訳の 2.5%スイス: 引用元論文 316 件、この内訳の 2.2%韓国: 引用元論文 311 件、この内訳の 2.2%
0%30.6%その他 20.9%

機関

分野

  • Medicine62.6%
  • Biochemistry, Genetics and Molecular Biology20%
  • Immunology and Microbiology11.6%
  • Engineering1.6%
  • Materials Science0.9%
  • Chemistry0.6%
  • その他2.7%

トピック

  • Lung Cancer Treatments and Mutations11.7%
  • Lung Cancer Research Studies7.1%
  • Lung Cancer Diagnosis and Treatment4.8%
  • T-cell and Retrovirus Studies3.7%
  • Cancer Immunotherapy and Biomarkers3.2%
  • Cancer Genomics and Diagnostics3%
  • その他66.5%

共著者

全論文

検索で開く
  1. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

    著者: Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Höetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, F Rényi-Vámos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, Balázs Döme - CA A Cancer Journal for Clinicians 2023 被引用: 343

  2. Small-cell lung cancer: what we know, what we need to know and the path forward

    著者: Adi F. Gazdar, Paul A. Bunn, John D. Minna - Nature reviews. Cancer 2017 被引用: 920

  3. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    著者: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 被引用: 1,744

  4. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

    著者: William D. Travis, Sanja Đačić, Ignacio I. Wistuba, Lynette M. Sholl, Prasad S. Adusumilli, Lukas Bubendorf, Paul A. Bunn, Tina Cascone, Jamie E. Chaft, Gang Chen, Teh‐Ying Chou, Wendy A. Cooper, Jeremy J. Erasmus, Carlos Gil Ferreira, Jin-Mo Goo, John V. Heymach, Fred R. Hirsch, Hidehito Horinouchi, Keith M. Kerr, Mark G. Kris, Deepali Jain, Young Tae Kim, Fernando López‐Ríos, Shun Lü, Tetsuya Mitsudomi, André Moreira, Noriko Motoi, Andrew G. Nicholson, Ricardo Oliveira, Mauro Papotti, Ugo Pastorino, Luis Paz‐Ares, Giuseppe Pelosi, Claudia Poleri, Mariano Provencio, Anja C. Roden, Giorgio V. Scagliotti, Stephen G. Swisher, Erik Thunnissen, Ming‐Sound Tsao, Johan Vansteenkiste, Walter Weder, Yasushi Yatabe - Journal of Thoracic Oncology 2020 被引用: 450

  5. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

    著者: Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał T. Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, LCMC study investigators, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg - Nature Medicine 2022 被引用: 237

  6. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

    著者: Bernard J. Poiesz, Francis W. Ruscetti, Adi F. Gazdar, Paul A. Bunn, John D. Minna, Robert C. Gallo - National Academy of Sciences, Proceedings of the National Academy of Sciences 1980 被引用: 5,075

  7. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

    著者: Rathi N. Pillai, Madhusmita Behera, Lynne D. Berry, Mike R. Rossi, Mark G. Kris, Bruce E. Johnson, Paul A. Bunn, Suresh S. Ramalingam, Fadlo R. Khuri - Cancer 2017 被引用: 201

  8. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib

    著者: Tejas Patil, Derek Smith, Paul A. Bunn, Dara L. Aisner, Anh T. Le, Mark J. Hancock, W. Thomas Purcell, Daniel W. Bowles, D. Ross Camidge, Robert C. Doebele - Journal of Thoracic Oncology 2018 被引用: 199

  9. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

    著者: Andrew Weickhardt, Benjamin Scheier, Joseph Burke, Gregory N. Gan, Xian Lu, Paul A. Bunn, Dara L. Aisner, Laurie E. Gaspar, Brian D. Kavanagh, Robert C. Doebele, D. Ross Camidge - Journal of Thoracic Oncology 2012 被引用: 677

  10. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

    著者: Lynette M. Sholl, Dara L. Aisner, Marileila Varella‐Garcia, Lynne D. Berry, Dora Dias‐Santagata, Ignacio I. Wistuba, Heidi Chen, Junya Fujimoto, Kelly Kugler, Wilbur A. Franklin, A. John Iafrate, Marc Ladanyi, Mark G. Kris, Bruce E. Johnson, Paul A. Bunn, John D. Minna, David J. Kwiatkowski - Journal of Thoracic Oncology 2015 被引用: 430

  11. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    著者: Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather A. Wakelee, Nick Thatcher - Journal of Thoracic Oncology 2017 被引用: 243

  12. New and emerging targeted treatments in advanced non-small-cell lung cancer

    著者: Fred R. Hirsch, Kenichi Suda, Jacinta Wiens, Paul A. Bunn - The Lancet 2016 被引用: 487

  13. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

    著者: Y. Wang, Tao Jiang, Zhen Qin, Jinghui Jiang, Qiang Wang, Seung Hee Yang, Christopher J. Rivard, G. Gao, Tony L. Ng, Megan M. Tu, Hui Yu, Huiping Ji, Caicun Zhou, Shengxiang Ren, Jun Zhang, Paul A. Bunn, Robert C. Doebele, D. Ross Camidge, Fred R. Hirsch - Annals of Oncology 1999 被引用: 217

  14. Clinicopathologic Features of Advanced Squamous NSCLC

    著者: Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher - Journal of Thoracic Oncology 2016 被引用: 197

  15. Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer

    著者: Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth A. Jones, Laura Schubert, Andrea E. Doak, Adriana Estrada‐Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn, W. Tom Purcell, Rafał Dziadziuszko, Marileila Varella‐Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele - Clinical Cancer Research 2018 被引用: 246

  16. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

    著者: Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D. Berry, Gabriel Sica, Rathi N. Pillai, Taofeek K. Owonikoko, Mark G. Kris, Bruce E. Johnson, David J. Kwiatkowski, Lynette M. Sholl, Dara L. Aisner, Paul A. Bunn, Fadlo R. Khuri, Suresh S. Ramalingam - Journal of Thoracic Oncology 2019 被引用: 241

  17. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

    著者: Robin Guo, Lynne D. Berry, Dara L. Aisner, Jamie Sheren, Theresa A. Boyle, Paul A. Bunn, Bruce E. Johnson, David J. Kwiatkowski, Alexander Drilon, Lynette M. Sholl, Mark G. Kris - Journal of Thoracic Oncology 2019 被引用: 174

  18. Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

    著者: Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn, Michael V. Di Maria, Robert Veve, Roy M. Bremnes, Anna E. Barón, Chan Zeng, Wilbur A. Franklin - Journal of Clinical Oncology 2003 被引用: 1,489

  19. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

    著者: Dávid Dóra, Christopher J. Rivard, Hui Yu, Paul A. Bunn, Kenichi Suda, Shengxiang Ren, Shivaun Lueke Pickard, Viktória László, Tünde Harkó, Zsolt Megyesfalvi, Judit Moldvay, Fred R. Hirsch, Balázs Döme, Zoltán Lohinai - Molecular Oncology 2020 被引用: 86

  20. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

    著者: Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo de Marinis, Joachim von Pawel, U. Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Müller, Hong-Liang Lim, Christopher E. Desch, Klára Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn - Journal of Clinical Oncology 2004 被引用: 2,433

  21. Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

    著者: Samir E. Witta, Robert M. Jotte, Katrik Konduri, Marcus A. Neubauer, Alexander I. Spira, Robert L. Ruxer, Marileila Varella‐Garcia, Paul A. Bunn, Fred R. Hirsch - Journal of Clinical Oncology 2012 被引用: 195

  22. Erratum: Small-cell lung cancer: what we know, what we need to know and the path forward

    著者: Adi F. Gazdar, Paul A. Bunn, John D. Minna - Nature reviews. Cancer 2017 被引用: 141

  23. Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess

    著者: Tore Lindmo, Epie Boven, Frank Cuttitta, J Fedorko, Paul A. Bunn - Journal of Immunological Methods 1984 被引用: 937

  24. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

    著者: Fred R. Hirsch, M. Varella-Garcia, Wilbur A. Franklin, Robert Veve, L Chen, B. Helfrich, Chan Zeng, Anna E. Barón, Paul A. Bunn - British Journal of Cancer 2002 被引用: 247